Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Common Equity (2016 - 2025)

Utah Medical Products (UTMD) has 16 years of Common Equity data on record, last reported at $118.3 million in Q3 2025.

  • For Q3 2025, Common Equity fell 4.79% year-over-year to $118.3 million; the TTM value through Sep 2025 reached $118.3 million, down 4.79%, while the annual FY2024 figure was $117.4 million, 8.48% down from the prior year.
  • Common Equity reached $118.3 million in Q3 2025 per UTMD's latest filing, up from $117.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $128.3 million in Q4 2023 and bottomed at $104.9 million in Q1 2021.
  • Average Common Equity over 5 years is $116.1 million, with a median of $117.4 million recorded in 2024.
  • Peak YoY movement for Common Equity: rose 14.34% in 2023, then fell 8.48% in 2024.
  • A 5-year view of Common Equity shows it stood at $107.1 million in 2021, then increased by 6.64% to $114.3 million in 2022, then rose by 12.3% to $128.3 million in 2023, then dropped by 8.48% to $117.4 million in 2024, then grew by 0.7% to $118.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $118.3 million in Q3 2025, $117.5 million in Q2 2025, and $117.0 million in Q1 2025.